NasdaqGS:MGNXBiotechs
MacroGenics (MGNX) Loss Of US$74.6 Million Tests Bullish Loss‑Narrowing Narrative
MacroGenics (MGNX) has wrapped up FY 2025 with fourth quarter revenue of US$41.2 million and a basic EPS loss of US$0.22, as the market weighs these results against a share price of US$3.43. The company has seen revenue move from US$110.7 million in Q3 2024 to US$72.8 million in Q3 2025, while basic EPS shifted from a profit of US$0.90 to a profit of US$0.27 over the same period, creating a mixed picture on topline scale and per share results. Overall, margins remain under pressure, which...